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Abstract 
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of both hospital- and community-acquired infections 
worldwide. However, data about the molecular epidemiology of MRSA in North Africa are still scarce. 
Methodology: All MRSA isolates recovered between January 2006 and July 2011 from one Algerian hospital were genetically and 
phenotypically characterized. 
Results: The predominance of a European community-associated-MRSA (CA-MRSA) clone (ST80-SCCmec IV-PVL positive) was revealed 
by this analysis. 
Conclusion: Our data suggest that a CA-MRSA clone recently invaded the hospital setting in Algiers and replaced a typical hospital-
associated pandemic clone such as the Brazilian clone (ST239-SCCmec IIImercury-PVL negative). 
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Introduction 
Methicillin-resistant Staphylococcus aureus 
(MRSA) is a major cause of both hospital and 
community-acquired infections worldwide. However, 
there is a considerable epidemiological variation of 
MRSA at both regional and global levels [1]. For 
example, Mediterranean countries likely represent a 
hyperendemic region for MRSA whereas the 
proportion of MRSA in northern Europe is much 
lower [2].
 
In particular, the proportion of MRSA in 
southern Mediterranean countries (e.g., Egypt, Tunisia 
and Algeria) showed a recent spectacular increase [2].
 
Nevertheless, data about the molecular epidemiology 
of MRSA in North Africa are still scarce compared to 
European countries. 
 
Methodology 
In this study, all MRSA isolates (one per patient; n 
= 84) recovered between January 2006 and July 2011 
from the Bologhine Ibn Ziri University hospital (250 
beds) located in Algiers (Algeria) were characterized. 
The epidemiological characteristics of these isolates 
are indicated in Table 1-S. Each bacterial isolate was 
identified with standard bacteriological procedures 
(i.e., Gram stain, colonial/morphological appearance, 
tube coagulase, catalase and DNase tests); 
susceptibility to 12 common antimicrobial agents 
(Table 1) was tested using the disc-diffusion method 
according to the Clinical and Laboratory Standards 
Institute (CLSI) guidelines [3]. 
The genetic diversity of this MRSA population 
was assessed with the highly discriminatory Double 
Locus Sequence Typing (DLST) method as previously 
described [4,5].
 
This method is based on the analysis 
of partial sequences (about 500 base pairs) of the 
variable clfB and spa genes. Additionally, the 
staphylococcal cassette chromosome (SCCmec) 
element was determined in each strain using a 
multiplex PCR method described by Kondo et al.; the 
presence of Panton-Valentine-leukocidin  (PVL) genes 
was tested as previously described [6,7]. 
 
Results and discussion 
As expected, all MRSA isolates were resistant to 
penicillin, oxacillin and cefoxitin (Table 1). In 
contrast, all isolates were susceptible to rifampin, 
vancomycin and teicoplanin. Variable resistance rates 
were observed for kanamycin (77.4%), tetracycline 
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(58.3%), clindamycin (9.5%), co-trimoxazole (23.8%), 
ofloxacin (15.5%) and fusidic acid (53.6%). 
A total of 13 clfB and 5 spa alleles were observed 
among the 84 MRSA isolates typed by DLST and 
these accounted for 13 different DLST types. eBURST 
software was used to cluster DLST types sharing at 
least one identical allele (http://eburst.mlst.net/). There 
is generally a good concordance between DLST 
clusters and MLST clonal complexes and it is possible 
to relate these clusters with international clones [8]. 
This analysis identified two main clusters as well as 
three singletons (Figure 1). First, the cluster with 
DLST ancestor 415-26 represents 85.7% (72/84) of all 
isolates. This cluster corresponds to the European CA-
MRSA clone (ST80) and as expected all isolates of 
this clone were PVL positive [5]. In addition, most 
isolates of this clone carry the SCCmec type IV 
although it was not possible to identify the ccr type in 
two isolates. Second, the clone with DLST type 28-30 
represents 8.3% (7/84) of all isolates. This cluster is 
related to the Brazilian clone (ST239) and as expected 
all the isolates of this clone carried the SCCmec 
IIImercury and were PVL negative [5]. Finally, the 
remaining five isolates (6.0%) belonged to three single 
DLST types and could not be associated with 
international clones. All these isolates carried the 
SCCmec IV and were PVL negative. 
The European CA-MRSA (ST80-IV-pos) is the 
most common community acquired clone in Europe 
[9,10].
 
Although this clone has been recovered from 
many European countries, it has often been associated 
with patients with Middle Eastern or North African 
origin [9,10]. This is probably explained by the 
predominance of the European CA-MRSA clone in 
Algeria and in surrounding North African countries 
[11-15].
 
Even though this clone is generally associated 
with community-acquisitions, our data did not allow 
discrimination between hospital and community 
acquisitions. Nevertheless, the widespread occurrence 
of this clone in Algerian hospitals indicates it has 
invaded the hospital setting. Moreover, the proportion 
of isolates belonging to ST80 changed during our 
study period. Whereas a similar proportion of the 
Brazilian and European CA-MRSA clone was 
observed in 2006 (36% vs. 43%), the European CA-
MRSA clone accounted for > 90% of the isolates in 
subsequent years (Table 2). This observation as well 
as similar previous observations suggest a recent 
Table 1. Patterns of susceptibility of the European CA-MRSA and Brazilian clones as well as overall Algerian MRSA isolates. 
 
Resistant isolates (%) among: 
 
European CA-MRSA isolates 
(ST80) 
Brazilian MRSA isolates 
(ST239) 
All isolates 
Antibiotic (n = 72) (n = 7) (n = 84) 
Penicillin 100 100 100 
Oxacillin 100 100 100 
Cefoxitin 100 100 100 
Kanamycine 69.3 100 77.4 
Tetracycline 55.6 71.4 58.3 
Clindamycin 8.3 0 9.5 
Co-trimoxazole 20.8 57.1 23.8 
Ofloxacine 8.3 71.4 15.5 
Rifampin 0 0 0 
Vancomycin 0 0 0 
Teichoplanine 0 0 0 
Fusidic acid 55.6 42.9 53.6 
 
Figure 1. DLST single-locus variant clustering of 84 S. aureus 
isolates from the Bologhine Ibn Ziri University hospital in 
Algeria using eBURST. Each circle represents one DLST type, 
and the diameter of the circle reflects the frequency (i.e., the 
number of isolates) of that type. Linked DLST types differ at 
one of the two loci (clfB or spa). SCCmec type is indicated 
next to each DLST type (“Un” indicates isolates with unknown 
ccr type) and each DLST types including PVL-positive isolates 
are indicated by asterisks. Two isolates had a null allele (i.e. 0) 
at the spa locus. The name of the international clone associated 
with each of the main cluster is indicated under the cluster. 
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emergence of the ST80 clone in Algerian hospitals and 
indicate that this community associated clone is able to 
quickly replace typical hospital-associated clones such 
as the Brazilian clone [12,14]. 
To compare the antibiotic susceptibility and 
virulence patterns of the major clones recovered in this 
study with international clones, we analyzed two 
representative Algerian isolates of the European CA-
MRSA clone and one Algerian isolate of the Brazilian 
clone with the Alere StaphyType DNA microarray 
(Alere Technologies, Jena, Germany) [16]. This 
microarray targets approximately 170 distinct genes 
and it was used following protocols and procedure 
previously described into detail [16]. Interestingly, the 
presence/absence of resistance and virulence genes for 
each major Algerian clone was similar to other isolates 
of the same clone as reported by Monecke (Table 2-S) 
[16]. This confirms the general homogeneity among 
Algerian and European isolates of the ST80 clone 
[10]. 
In conclusion, our data confirmed the 
predominance of the PVL-positive European CA-
MRSA (ST80-IV-pos) clone in Algeria. In addition, 
our findings suggest that this clone recently replaced 
other hospital associated pandemic clones in Algerian 
hospitals. 
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Supplementary Items 
Table 1-S: Characteristics of the 84 Algerian MRSA recovered in the Bologhine Ibn Ziri University hospital (Algiers, Algeria). 
Strain 
Year of 
isolation 
gender Child/Adult Service Specimen PVL clfB spa mecA SCCmec International Clone Antibiotic resistance profile a 
22579 2006 F Adult Out Furuncle pos 563 26 pos ND b European CA-MRSA (ST80) P,OXA,K, 
22573 2006 M NA NA Wound pos 562 26 pos IV European CA-MRSA (ST80) P,OXA,K, 
22576 2006 M Adult Medicine Pus pos 560 26 pos IV European CA-MRSA (ST80) P, OX, K,  TE, FA 
22582 2006 F Adult Medicine Furuncle pos 561 26 pos IV European CA-MRSA (ST80) P, OX, K, FA, TE, 
22581 2006 M Adult Surgery NA pos 46 26 pos IV European CA-MRSA (ST80) P, OX, TE, K, FA 
22574 2006 M Adult Medicine Pus neg 28 30 pos IIImercury Brazilian Clone (ST239) P, OX,  K, GM, OFX 
22571 2006 M Adult Emergency Wound neg 366 252 pos IV Other P, OX,  K, TE 
22583 2006 M Adult Emergency Wound neg 28 30 pos IIImercury Brazilian Clone (ST239) P, OX,  K, TE 
22584 2006 NA NA NA NA neg 28 30 pos IIImercury Brazilian Clone (ST239) P,OXA,K,T,FA,E,SXT,OFX 
22578 2006 M Adult Emergency Wound neg 28 30 pos IIImercury Brazilian Clone (ST239) P, OX,, K, TE,,FA, OFX, SXT 
22575 2006 M Adult Emergency Wound neg 366 252 pos IV Other P, OX,, K, TE,FA, OFX, SXT 
22577 2006 M Adult Emergency Wound neg 28 30 pos IIImercury Brazilian Clone (ST239) P, OX,, K, TE,FA, OFX, SXT 
22572 2006 NA NA NA NA neg 366 252 pos IV Other P,OXA,K, 
22580 2006 M Adult Out Wound pos 7 26 pos IV European CA-MRSA (ST80) P,OXA,K, 
22593 2007 F Adult Out Pus pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,TE 
22599 2007 F Adult Surgery Blood pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K-TE 
22594 2007 F Adult NA Pus pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,T,K,FA 
22595 2007 F Adult Out Pus pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,OFX-CM-SXT 
22598 2007 F Child Pediatrics Pus pos 559 26 pos IV European CA-MRSA (ST80) P,OXA,K 
22596 2007 F NA NA Pus pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,AF-K 
22597 2007 F NA Out Pus pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K-TE-FA 
22600 2007 M Child Pediatrics Blood pos 415 26 pos IV European CA-MRSA (ST80) P,OXA 
22601 2007 F Child Pediatrics Blood pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,FA-SXT 
22618 2008 NA NA Surgery NA pos 7 26 pos IV European CA-MRSA (ST80) P,OXA,FA,SXT 
22613 2008 F Child Pediatrics NA pos 559 26 pos IV European CA-MRSA (ST80) P,OXA,K,T,FA 
22603 2008 F Adult Out Nose pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K-FA 
22615 2008 NA NA Surgery NA pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,FA 
22604 2008 F Adult Out Furuncle pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K 
22617 2008 M Child Out Pus pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,K 
22612 2008 NA NA NA NA pos 559 26 pos IV European CA-MRSA (ST80) P,OXA,FA,SXT 
22620 2008 M Adult Surgery Blood pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,SXT 
22616 2008 NA NA NA NA pos 559 26 pos IV European CA-MRSA (ST80) P,OXA,K-TE 
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Table 1-S: continued 
Strain 
Year of 
isolation 
gender Child/Adult Service Specimen PVL clfB spa mecA SCCmec International Clone  Antibiotic resistance profile a 
22614 2008 M Adult Surgery NA pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,TE-FA-OFX 
22605 2008 NA NA NA NA pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K,T,FA 
22619 2008 M Child Pediatrics Blood pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K  
22606 2008 F Adult Intensive care NA pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K 
22607 2008 M Adult Intensive care Pus pos 415 0 pos ND b European CA-MRSA (ST80) P,OXA,K,CM 
22608 2008 F Adult Gynecology Pus pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K-SXT-OFX-FA 
22609 2008 F Adult Surgery Furuncle pos 559 26 pos IV European CA-MRSA (ST80) P,OXA,K,TE,FA 
22621 2008 F Adult Out Urine pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,FA 
22610 2008 F Adult Intensive care Pus neg 117 102 pos II Other P,OXA,K,CM 
22611 2008 F Adult NA Pus pos 573 26 pos IV European CA-MRSA (ST80) P,OXA,TE,K,CM 
22602 2008 F Adult Out Groin pos 559 26 pos IV European CA-MRSA (ST80) P,OXA,K 
22631 2009 F Adult Out Nose pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,TE,K,FA 
22632 2009 M Adult Out Groin pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,TE,FA 
22633 2009 F Adult Surgery Groin pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K-TE-SXT 
22634 2009 H Adult Out NA pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,K-OFX-FA 
22635 2009 F Child Pediatrics Furuncle pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K,T,FA 
22636 2009 F Adult Out NA pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K,T 
22637 2009 F Adult Out Pus pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K,T,CM 
22655 2009 H Child Pediatrics Blood pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,K,TE-FA-SXT 
22652 2009 H Adult Medicine Blood pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,FA 
22639 2009 F NA NA Pus pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,K-TE-FA 
22656 2009 NA NA NA NA pos 559 26 pos IV European CA-MRSA (ST80) P,OXA 
22641 2009 H NA NA Pus pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,K,FA-SXT 
22642 2009 H Child Pediatrics Pus pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,TE-K 
22643 2009 F Adult Intensive care Pus pos 559 26 pos IV European CA-MRSA (ST80) P,OXA,K,FA,SXT 
22644 2009 H Adult Out Wound pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,K.T,FA 
22653 2009 F Adult NA Blood pos 46 26 pos IV European CA-MRSA (ST80) FA-SXT 
22629 2009 F Adult Gynecology NA pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,TE 
22645 2009 F Adult Gynecology Pus pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K-TE-FA 
22646 2009 H Adult Gynecology Pus pos 559 26 pos IV European CA-MRSA (ST80) P,OXA,K-TE-FA,SXT 
22647 2009 H Child Pediatrics Rectal pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,K-T,FA 
22648 2009 F Adult Out Nose pos 7 26 pos IV European CA-MRSA (ST80) P,OXA,K,TE-FA 
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Table 1-S: continued 
Strain 
Year of 
isolation 
gender Child/Adult Service Specimen PVL clfB spa mecA SCCmec International Clone  Antibiotic resistance profile a 
22649 2009 H Adult Out Nose pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,K,T,FA 
22654 2009 F Adult NA Blood pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,FA,CM 
22630 2009 M Adult Out Groin pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K-TE-FA 
22650 2009 F Adult Gynecology Nose pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,K,FA-CM-OFX-SXT 
22651 2009 F Adult Gynecology Pus pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,K,T,FA-SXT 
22585 2010 F Adult Out Nose pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,K,T,FA 
22590 2010 H Adult NA Pus neg 28 30 pos IIImercury Brazilian Clone (ST239) P,OXA,K-TE-OFX 
22587 2010 H Adult Out Wound pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,TE 
22588 2010 F Child Out Wound pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,TE 
22592 2010 H Adult Intensive care Blood neg 28 30 pos IIImercury Brazilian Clone (ST239) P,OXA,K-OFX 
22591 2010 F Adult Gynecology Pus pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,FA-SXT 
22628 2010 H Adult Intensive care Pus pos 7 26 pos IV European CA-MRSA (ST80) P,OXA,K,FA 
22589 2010 F Adult NA Pus pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,K,FA,CM 
23878 2011 M Adult Medicine Blood pos 7 26 pos IV European CA-MRSA (ST80) P,OXA,K,T,FA 
23872 2011 M Adult Medicine Blood pos 7 26 pos IV European CA-MRSA (ST80) P,OXA,K,T,FA 
23879 2011 M Adult Intensive care Blood pos 7 26 pos IV European CA-MRSA (ST80) P,OXA,K,T,FA 
23873 2011 F Adult NA Pus pos 415 26 pos IV European CA-MRSA (ST80) P,OXA,K,T,FA 
23874 2011 M Adult Medicine Pus pos 7 26 pos IV European CA-MRSA (ST80) P,OXA,K,T,FA 
23876 2011 F Adult Gynecology Pus pos 46 26 pos IV European CA-MRSA (ST80) P,OXA,K,T,FA 
23877 2011 F NA Out Groin neg 2 0 pos IV Other P,OXA,K,T,FA,SXT 
a P = penicillin, OXA= oxacillin, K= kanamycine, TE = tetracycline, CM = clindamycin, SXT = Co-trimoxazole, OFX = ofloxacin, FA = fusidic acid ; b Not determined, unusual SCCmec element (no amplification of the ccr 
type with the Kondo et al. 2006 primers) 
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Table 2-S: Presence/absence of resistance- (A) and virulence- (B) associated genes as detected with the Alere StaphyType DNA microarray (Monecke et al. 2011, PLoS One 6(4): 
e17936). 
(A) 
European CA-
MRSA (22599) 
European CA-
MRSA (22654) 
Brazilian Clone 
(22590) 
(B) 
European CA-
MRSA (22599) 
European CA-
MRSA (22654) 
Brazilian Clone 
(22590) 
blaZ neg pos pos PVL genes pos pos neg 
erm(A) neg neg pos ACME neg neg neg 
erm(B) neg neg neg sak pos pos pos 
erm(C) neg neg neg chp neg neg pos 
lnu(A) neg neg neg scn pos pos neg 
msr(A) neg neg neg sea neg neg neg 
mph(C ) neg neg neg seb neg neg neg 
vga(A) neg neg neg sek & seq neg neg pos 
aacA-aphD neg pos pos sec & sel neg neg neg 
aadD neg neg neg tst1 neg neg neg 
aphA3 &sat pos pos pos sed neg neg neg 
dfrA neg neg neg sej & ser neg neg neg 
far1 neg neg neg egc-genes neg neg neg 
Q6GD50 neg neg neg seh neg neg neg 
mupA neg neg neg etA neg neg neg 
tet(K) neg neg neg etD pos pos neg 
tet(M) neg neg pos edinA neg neg neg 
cat neg neg neg edinB pos pos neg 
cfr neg neg neg splA & splB pos pos neg 
fexA neg neg neg hld neg neg pos 
qacA neg neg neg aur neg neg pos 
qacC neg neg neg 
    
mercA & merB neg neg neg 
    
fosB neg neg pos 
    
 
 
B
as
se
t 
et
 a
l.
 –
 M
o
le
cu
la
r 
ep
id
em
io
lo
g
y
 o
f 
M
R
S
A
 i
n
 A
lg
er
ia
 
 
 
 
 
J 
In
fe
ct
 D
ev
 C
tr
ie
s 
2
0
1
5
; 
9
(2
):
2
0
6
-2
0
9
 
